I-SPY COVID-19 (NCT04488081) is a phase 2, multi-centre, open-label, platform clinical trial designed by Quantum Leap Healthcare Collaborative™ to rapidly evaluate repurposed and investigational agents in critically ill patients infected with SARS-CoV-2. In this interview, we speak with Prof. Angela Haczku (University of California at Davis, CA, USA), one of the study investigators for the cyclosporine arm of the study. Cyclosporine is a frequently prescribed immunosuppressant that was hypothesized to be of potential benefit in critically ill patients with COVID-19 due to its possible ability to suppress the ‘cytokine storm’ and hence reduce the chance of COVID-19-related lung injury. However, the testing of cyclosporine in I-SPY COVID-19 was recently discontinued when the drug failed to meet the pre-defined primary outcome criteria. In this interview, we discuss the trial and its results in more detail.
- What is the rationale for the use of cyclosporine in patients hospitalized with COVID-19? (0:17)
- What were the aims and design of the I-SPY COVID trial? (0:58)
- Why was the cyclosporine arm terminated? (3:05)
- What factors might have contributed to this disappointing finding, and what questions remain unanswered? (4:14)
- What are the future goals for the I-SPY study? (6:36)
Disclosures: Angela Haczku has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In COVID-19
Ruth Link-Gelles, IDWeek 2022: Efficacy of COVID-19 vaccination in paediatric populations
In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss the incidence of COVID-19 in children, vaccine effectiveness against infection and disease severity, and the current status of paediatric COVID-19 vaccines in the United States. Interviews available in this series: Real world […]
Ruth Link-Gelles, IDWeek 2022: Real world effectiveness of paediatric COVID-19 vaccination
COVID-19 typically causes less severe illness and fewer deaths in children and adolescents compared to adults. Nonetheless, children and adolescents remain susceptible to COVID-19 infection and can transmit to others. In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss real-world findings of […]
Angus Thomson: Communicating with patients about their vaccinations – Communication methods, support and counteracting disinformation
In this interview, Dr Angus Thomson (Irimi Company, Lyon, France) discusses effective methods for communicating with patients about their vaccinations, how healthcare professionals (HCPs) can help to counteract disinformation, and additional resources for HCPs and patients. Interviews available in this series: Angus Thomson: Barriers to vaccine acceptance in a post-COVID world Angus Thomson: Zero-dose children: […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!